April 14, 2021
Business News

AcornMed Selects Twist Bioscience Technology to Power Next Generation Precision Medicine Tests


SOUTH SAN FRANCISCO, Calif & BEIJING–()–AcornMed Biotechnology Co., Ltd. (AcornMed), a precision medicine organization that specializes in the testing and analysis of solid and blood tumors, announced today that they will incorporate Twist Bioscience next generation sequencing (NGS) target enrichment and library preparation panels into AcornMed’s portfolio of tests designed to provide insight into the genetic predisposition and treatment regimens for patients, providing a more targeted therapeutic approach.

“The partnership between Twist and AcornMed provides us with access to the global leader in high quality DNA synthesis at scale and quality. Twist understands the importance of panel performance and…



Click here to view the original article.

Related Posts

You might also like ...

AON Splash Image
Resumen: Smiths Detection confirma que BioFlash es capaz de detectar la COVID-19 en el aire
Africa’s Best Corporate-Startup Collaboration Accelerator, Startupbootcamp AfriTech, Now Open for Applications from the Most Disruptive Startups
Minnesota Department of Transportation Leverages Iteris’ ClearMobility Cloud for Improved Statewide Mobility